Observational Study of LUMRYZ in Narcolepsy (REFRESH)

Avadel Pharmaceuticals

Status: Active, not recruiting

Conditions: Narcolepsy

Treatments: Drug: LUMRYZ

Study type: Observational

Funder types: Industry

Identifiers

NCT06792708

PMLUM-2402

Details and patient eligibility

About

This is an observational study of LUMRYZ prescribed in clinical practice. Patients are asked if they would be willing to complete questionnaires over a 4-month period after starting LUMRYZ. The questionnaires ask about narcolepsy symptoms, experience with LUMRYZ, and quality of life.

Enrollment: 75 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults with narcolepsy
• Oxybate naive or prior treatment with twice-nightly oxybate
• Access to smart phone, tablet or laptop with reliable internet connection
• Able to read/understand English
• Written informed consent and ability to comply with schedule

Exclusion criteria

• Already using LUMRYZ
• Clinical or mental health condition excluded by LUMRYZ label
• Any other condition/situation that would adversely impact participation

Trial design

75 participants in 1 patient group

Patients Starting LUMRYZ

Description:

The cohort is comprised of patients prescribed LUMRYZ in clinical practice. All dosing decisions are made by the clinician.

Treatment:

Drug: LUMRYZ